Is Pfizer Stock a Buy Now?
(NYSE: PFE) sells a wide variety of medicines across treatment areas such as autoimmune diseases and oncology. But it probably is most known for its leading coronavirus vaccine, which helped the company reach a record of more than $100 billion in annual revenue last year. That didn't help Pfizer's share performance this year, though. The stock has slipped about 35%.
Why the share price declines after such strong revenue? Investors are worried about Pfizer's vaccine sales as we head toward a post-pandemic world, especially considering that vaccine demand has already started to decline. And Pfizer also faces patent expiration on other important products, representing additional lost revenue. But the big pharma company isn't resting on its laurels, and it may actually be transitioning into a new phase of growth. So, is the stock a buy now? Let's find out.
First, let's take a look at the risks today and down the road. The company sells COVID vaccine Comirnaty and COVID treatment Paxlovid, and demand for both products is on the decline. In fact, Pfizer predicts about $13.5 billion in Comirnaty revenue and $8 billion in Paxlovid revenue this year -- double-digit declines from last year's levels.
Source Fool.com
Pfizer Inc. Aktie
Überwältigendes Buy-Interesse bei Pfizer Inc., mit einer hohen Anzahl von Buy- und wenigen Sell-Einschätzungen.
Eine erhebliche Steigerung um mehr als 50% ist für Pfizer Inc. mit einem Kursziel von 41 € im Vergleich zum aktuellen Kurs von 26.82 € zu erwarten.
